乏氧诱导因子2ɑ拮抗剂在肾透明细胞癌中的应用前景

Application Prospect of Hypoxia Inducible Factor-1alpha 2ɑ Antagonist in the Suprarenal Epithelioma

缺氧是实体肿瘤的典型特征,也是导致肿瘤侵袭和产生放化疗耐受的重要原因。缺氧诱导因子(HIF)是肿瘤细胞耐受缺氧环境所必需的转录因子,可以促进血管生成、增加肿瘤的生长和代谢。研究表明,在肾透明细胞癌(ccRCC)中HIF-2α比HIF-1α的作用更加重要。HIF-2α拮抗剂作为ccRCC治疗药物也越发得到重视。最新研究表明,HIF-2α能够被选择性的小分子抑制剂PT2399和PT2385靶向攻击,利用这种治疗方法比使用抗血管生成药物产生的毒性低,对患者的治疗更加有利。然而,研究也发现不同个体对HIF-2α拮抗剂的敏感性不同,提示HIF-2α可以作为一种肿瘤标志物帮助判断患者的治疗效果和预后。

Hypoxia is the typical feature of solid tumors,and it is an important cause of tumor invasion and resistance to chemoradiotherapy,HIF is the transcription factor essential to the tumor cells resistance to hypoxia environment,which can promote the angiogenesis and increase the growth and metabolism of tumors,and the research shows that the effect of HIF-2αis more important than HIF-1αin the ccRCC,and the Hypoxia inducible factor-1alpha 2ɑantagonist,as the treatment drugs of ccRCC,has drawn more and more attention,and the new research shows that the selective small molecule inhibitor PT2399 and PT2385 can conduct the targeted attack of HIF-2α,and the toxicity produced by the treatment method is lower than that of antiangiogenic drugs,which is more conducive to the treatment of patients,however,the research also shows that the sensitivity of different individuals to the hypoxia inducible factor-1alpha 2ɑantagonist is different,which reminds that the HIF-2α,can help determine the treatment effect and prognosis of patients,as a kind of tumor markers.